Orchestra BioMed Holdings Statistics
Want to see OBIO full AI Analyst Report?
Orchestra BioMed Holdings (OBIO) Stock Statistics & Valuation Metrics
Total Valuation
Orchestra BioMed Holdings has a market cap or net worth of $341.40M. The enterprise value is $246.24M.
- Market Cap
- $341.40M
- Enterprise Value
- $246.24M
Share Statistics
Orchestra BioMed Holdings has 60,105,050 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 60,105,050
- Owned by Insiders
- 22.06%
- Owned by Institutions
- 14.57%
Financial Efficiency
Orchestra BioMed Holdings’s return on equity (ROE) is -0.83 and return on invested capital (ROIC) is -52.40%.
- Return on Equity (ROE)
- -0.83
- Return on Assets (ROA)
- -0.46
- Return on Invested Capital (ROIC)
- -52.40%
- Return on Capital Employed (ROCE)
- -0.53
- Revenue Per Employee
- 389.33K
- Profits Per Employee
- -612.80K
- Employee Count
- 86
- Asset Turnover
- 0.29
- Inventory Turnover
- 0.61
Valuation Ratios
The current PE Ratio of Orchestra BioMed Holdings is -5.76. Orchestra BioMed Holdings’s PEG ratio is -0.09.
- PE Ratio
- -5.76
- PS Ratio
- 10.71
- PB Ratio
- 12.36
- Price to FCF
- -5.80
- Price to Operating Cash Flow
- -6.24
- PEG Ratio
- -0.09
Income Statement
In the last 12 months, Orchestra BioMed Holdings had revenue of 33.48M and earned -52.70M in profits. Earnings per share was -1.11.
- Revenue
- 33.48M
- Gross Profit
- 33.29M
- Operating Income
- -51.81M
- Pretax Income
- -52.70M
- Net Income
- -52.70M
- EBITDA
- -51.23M
- Earnings Per Share (EPS)
- -1.11
Cash Flow
In the last 12 months, operating cash flow was -58.32M and capital expenditures -781,000, giving a free cash flow of -59.10M billion.
- Operating Cash Flow
- -58.32M
- Free Cash Flow
- -59.10M
- Free Cash Flow per Share
- -0.93
Dividends & Yields
Orchestra BioMed Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -17.34%
- Earnings Yield
- -16.31%
Stock Price Statistics
- Beta
- 1.71
- 52-Week Price Change
- 49.08%
- 50-Day Moving Average
- 5.74
- 200-Day Moving Average
- 4.58
- Relative Strength Index (RSI)
- 48.63
- Average Volume (3m)
- 374.50K
Important Dates
Orchestra BioMed Holdings upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Orchestra BioMed Holdings as a current ratio of 6.45, with Debt / Equity ratio of 25.17%
- Current Ratio
- 6.45
- Quick Ratio
- 6.43
- Debt to Market Cap
- 0.07
- Net Debt to EBITDA
- 0.37
- Interest Coverage Ratio
- -45.13
Taxes
In the past 12 months, Orchestra BioMed Holdings has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Orchestra BioMed Holdings EV to EBITDA ratio is -6.85, with an EV/FCF ratio of -6.62.
- EV to Sales
- 12.23
- EV to EBITDA
- -6.85
- EV to Free Cash Flow
- -6.62
- EV to Operating Cash Flow
- -6.71
Balance Sheet
Orchestra BioMed Holdings has $109.96M in cash and marketable securities with $70.76M in debt, giving a net cash position of $39.20M billion.
- Cash & Marketable Securities
- $109.96M
- Total Debt
- $70.76M
- Net Cash
- $39.20M
- Net Cash Per Share
- $0.65
- Tangible Book Value Per Share
- $0.46
Margins
Gross margin is 99.32%, with operating margin of -181.36%, and net profit margin of -184.60%.
- Gross Margin
- 99.32%
- Operating Margin
- -181.36%
- Pretax Margin
- -184.60%
- Net Profit Margin
- -184.60%
- EBITDA Margin
- -178.56%
- EBIT Margin
- -179.65%
Analyst Forecast
The average price target for Orchestra BioMed Holdings is $11.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $11.60
- Price Target Upside
- 104.23% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 5
- Revenue Growth Forecast
- 986.14%
- EPS Growth Forecast
- 45.31%
Scores
- Smart Score
- 9
- AI Score
- 50
